Casslén B, Gustavsson B, Astedt B
Department of Obstetrics and Gynecology, University Hospital, University of Lund, Sweden.
Eur J Cancer. 1991;27(11):1445-8. doi: 10.1016/0277-5379(91)90028-c.
The binding of 125I-labelled urokinase plasminogen activator (uPA) to cell membranes of ovarian tumours was characterised. Binding was fast, specific to HMW-uPA, and saturated at low concentration [1.5 (range 1.2-1.6) nmol/l]. Scatchard analysis suggested a single class of binding sites with Kd 1.1 (0.9-1.3) nmol/l. These data indicate the presence of a specific cell membrane receptor for uPA in ovarian tumours, whose characteristics are similar to those reported for uPA receptors in other tissues. Endogenously occupied receptors were uncovered by exposing the membranes to acid conditions (pH 2) before assay, thereby allowing quantitation of the total amount of receptor. uPA receptors were assayed in 10 malignant and 6 benign epithelial ovarian tumours. The total number of receptors was higher in the malignant tumours. This was secondary to increases of both free and occupied receptors. We conclude that this reflects the biological function of cell surface bound plasminogen activation in tumour growth and spread.
对125I标记的尿激酶型纤溶酶原激活剂(uPA)与卵巢肿瘤细胞膜的结合特性进行了表征。结合迅速,对高分子量uPA具有特异性,且在低浓度[1.5(范围1.2 - 1.6)nmol/L]时达到饱和。Scatchard分析表明存在一类结合位点,解离常数Kd为1.1(0.9 - 1.3)nmol/L。这些数据表明卵巢肿瘤中存在uPA的特异性细胞膜受体,其特性与其他组织中报道的uPA受体相似。在测定前将膜暴露于酸性条件(pH 2)下可揭示内源性占据的受体,从而能够对受体总量进行定量。在10例恶性上皮性卵巢肿瘤和6例良性上皮性卵巢肿瘤中检测了uPA受体。恶性肿瘤中的受体总数更高。这是游离受体和占据受体均增加的结果。我们得出结论,这反映了细胞表面结合的纤溶酶原激活在肿瘤生长和扩散中的生物学功能。